Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Sponsor: Andrei Iagaru
This PHASE2 trial investigates PSA Progression and Prostate Adenocarcinoma and is currently completed. Andrei Iagaru leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Jun 2022 — Jun 2023 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
▶ Show 7 earlier versions
-
Apr 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Aug 2020 — Dec 2020 [monthly]
Suspended PHASE2
Status: Not Yet Recruiting → Suspended
-
Feb 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Andrei Iagaru
For direct contact, visit the study record on ClinicalTrials.gov .